29.50
2.08%
0.60
Dopo l'orario di chiusura:
29.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BAX Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$28.90
Aprire:
$29.34
Volume 24 ore:
10.95M
Relative Volume:
2.75
Capitalizzazione di mercato:
$15.06B
Reddito:
$17.28B
Utile/perdita netta:
$108.00M
Rapporto P/E:
5.7843
EPS:
5.1
Flusso di cassa netto:
$391.00M
1 W Prestazione:
-2.70%
1M Prestazione:
-9.59%
6M Prestazione:
-13.24%
1 anno Prestazione:
-23.58%
Baxter International Inc Stock (BAX) Company Profile
Nome
Baxter International Inc
Settore
Industria
Telefono
(847) 948-2000
Indirizzo
ONE BAXTER PKWY, DEERFIELD, IL
Confronta BAX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
29.50 | 15.06B | 17.28B | 108.00M | 391.00M | 0.20 |
ISRG
Intuitive Surgical Inc
|
524.43 | 186.79B | 7.87B | 2.24B | 586.00M | 6.22 |
BDX
Becton Dickinson Co
|
227.68 | 65.83B | 20.18B | 1.71B | 3.07B | 5.94 |
ALC
Alcon Inc
|
84.76 | 41.92B | 9.76B | 1.16B | 665.00M | 2.34 |
RMD
Resmed Inc
|
237.27 | 34.83B | 4.81B | 1.11B | 1.35B | 7.55 |
WST
West Pharmaceutical Services Inc
|
331.40 | 24.00B | 2.88B | 499.60M | 321.60M | 6.74 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-07-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2024-05-30 | Iniziato | Goldman | Neutral |
2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
2023-03-29 | Iniziato | UBS | Neutral |
2023-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2023-01-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
2023-01-03 | Downgrade | BofA Securities | Buy → Neutral |
2022-12-19 | Downgrade | JP Morgan | Overweight → Neutral |
2022-12-15 | Downgrade | Deutsche Bank | Buy → Hold |
2022-12-12 | Downgrade | Citigroup | Buy → Neutral |
2022-10-18 | Iniziato | Barclays | Overweight |
2022-10-12 | Iniziato | Jefferies | Hold |
2022-06-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2022-04-04 | Downgrade | Goldman | Neutral → Sell |
2022-03-02 | Ripresa | BofA Securities | Buy |
2022-02-18 | Reiterato | KeyBanc Capital Markets | Overweight |
2022-02-18 | Reiterato | Morgan Stanley | Overweight |
2022-02-18 | Reiterato | Raymond James | Outperform |
2022-02-18 | Reiterato | Stifel | Buy |
2022-02-18 | Reiterato | UBS | Neutral |
2022-02-18 | Reiterato | Wells Fargo | Overweight |
2022-02-11 | Iniziato | Goldman | Neutral |
2022-01-07 | Ripresa | Citigroup | Buy |
2022-01-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2021-09-13 | Aggiornamento | Cowen | Market Perform → Outperform |
2021-09-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
2021-05-25 | Iniziato | Barclays | Equal Weight |
2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
2021-01-06 | Downgrade | UBS | Buy → Neutral |
2020-12-15 | Downgrade | Goldman | Buy → Neutral |
2020-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
2020-09-04 | Downgrade | Argus | Buy → Hold |
2020-06-24 | Iniziato | Oppenheimer | Outperform |
2020-03-19 | Aggiornamento | Stifel | Hold → Buy |
2020-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
2020-03-05 | Iniziato | Citigroup | Neutral |
2020-02-13 | Iniziato | Goldman | Buy |
2020-01-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
2019-12-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2019-06-26 | Iniziato | KeyBanc Capital Markets | Sector Weight |
2019-04-08 | Downgrade | Evercore ISI | Outperform → In-line |
2019-01-02 | Aggiornamento | Citigroup | Neutral → Buy |
2019-01-02 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
2018-11-02 | Aggiornamento | Argus | Hold → Buy |
2018-10-16 | Iniziato | Barclays | Underweight |
2018-05-17 | Ripresa | Piper Jaffray | Overweight |
2018-02-06 | Reiterato | Citigroup | Neutral |
2018-01-03 | Iniziato | Evercore ISI | Outperform |
2018-01-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
Mostra tutto
Baxter International Inc Borsa (BAX) Ultime notizie
Investors Purchase Large Volume of Baxter International Put Options (NYSE:BAX) - MarketBeat
Hurricane Helene impact on Baxter to further limit IV fluid supply, HHS says - AOL
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Baxter Resumes Production of Peritoneal Dialysis Solutions - DocWire News
Interesting BAX Put And Call Options For August 2025 - Nasdaq
Baxter International Inc. (NYSE:BAX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Baxter International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Baxter stock hits 52-week low at $29.14 amid market challenges - Investing.com Australia
Parenteral Nutrition Market May Set Epic Growth Story | Baxter, Hospira, Pfizer - openPR
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter International's SWOT analysis: medical supplies stock faces mixed signals - Investing.com
Baxter International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Baxter International (NYSE:BAX) Hits New 1-Year LowTime to Sell? - MarketBeat
Toronto Dominion Bank Buys 22,787 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Fresenius Can't Stop Baxter's Effort To Save Dialysis Patent - Law360
Baxter Stock May Gain Following Five New Injectable Product Launches - Yahoo Finance
Geode Capital Management LLC Grows Holdings in Baxter International Inc. (NYSE:BAX) - MarketBeat
Advanced Wound Care Management Market Share to Rise At 5.1% CAGR, To Reach USD 17.50 Billion by 2034 | PMR - GlobeNewswire Inc.
Baxter International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Baxter launches five injectable pharmaceutical products in US - World Pharmaceutical Frontiers
Tympanometer Market Top Companies StudyDemant Group, Baxter International, Oscilla Hearing, Amplifon SpA. - openPR
Baxter Announces Continued Growth of Pharmaceuticals Portfolio With Five Injectable Product Launches in the U.S. - Business Wire
Empire Financial Management Company LLC Buys 19,500 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter Announces Continued Growth of Pharmaceuticals Portfolio with Five Injectable Product Launches in the U.S. - Baxter
Baxter International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Oversold Conditions For Baxter International (BAX) - Nasdaq
Is the Options Market Predicting a Spike in Baxter International (BAX) Stock? - MSN
Baxter stock touches 52-week low at $31.6 amid market challenges - Investing.com Canada
José Almeida: 100 Most Influential People in Healthcare 2024 - Modern Healthcare
Adalta Capital Management LLC Sells 16,353 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Drug Delivery Market Overview and Leading Players: Baxter - openPR
Hurricane Pauses IV Production At Baxter's North Carolina Facility - MSN
Baxter International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Baxter’s Sascha Hanselmann on championing LGBTQ+ inclusion and building authentic workspaces - attitude.co.uk
Disposable Endoscope Market Report 2024 - GlobeNewswire Inc.
Baxter restarts dialysis solutions production at North Cove plant - MSN
Baxter restarts dialysis solutions production at North Cove plant (NYSE:BAX) - Seeking Alpha
Baxter resumes dialysis solution production at its hurricane-hit facility - Reuters
Baxter International Inc Azioni (BAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):